Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2000 Settembre;44(3) > The Quarterly Journal of Nuclear Medicine 2000 Settembre;44(3):236-55

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine 2000 Settembre;44(3):236-55

RADIOPHARMACOLOGY 

In vivo antisense imaging

Tavitian B.

From the ­INSERM U334 Service hos­pi­ta­li­er Frédéric Joliot, CEA/DSV, Orsay, France

Antisense oli­go­nu­cleo­tides, in ­short anti­sense, are ­small ­chains of nucle­ic ­acids ­capable to ­bind to cel­lu­lar ribo­nu­cle­ic ­acid (RNA) by a hybrid­iza­tion mech­a­nism. In ­vitro, anti­sense are wide­ly ­used as ­reagents to ­detect or ­block spe­cif­ic RNA sequenc­es. The use of anti­sense as in ­vivo diag­nos­tic ­agents is attrac­tive ­because it ­would ­bring molec­u­lar imag­ing at the lev­el of ­gene expres­sion. However, oli­go­nu­cleo­tides are non-canon­i­cal radio­phar­ma­ceu­ti­cals and ­much ­progress is need­ed to ­adapt ­them to in ­vivo imag­ing. The require­ments to ­reach ­this ­goal ­include improve­ments in radio­syn­the­sis, stabil­ity, tar­get­ing, and spe­cif­ic and non-spe­cif­ic bind­ing. They ­will be exam­ined in ­this ­review togeth­er ­with the cur­rent achieve­ments in the appli­ca­tions of anti­sense as nucle­ar med­i­cine radio­phar­ma­ceu­ti­cals.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina